Issues Surrounding the Management of Patients Who Present to the ED with Subtherapeutic Phenytoin Levels and a History of Seizures J. Stephen Huff, MD.

Slides:



Advertisements
Similar presentations
Oxford University Hospitals NHS Trust Injectable medicines study day:
Advertisements

First Line Therapy in Acute Seizure Management William C. Dalsey, MD, MBA, FACEP Department of Emergency Medicine Robert Wood Johnson University Hospital.
MANAGING SUBTHERAPEUTIC AED LEVELS Edwin Kuffner, MD, FACEP Rocky Mountain Poison and Drug Center Denver, Colorado.
Complications of IV drug Therapy March Site of administration Benefits?Complications?
J. Stephen Huff, MD, FACEP Critical Issues in the Evaluation and Management of Adult Patients Presenting to the ED with Seizures: The 2004 ACEP Clinical.
Status Epilepticus-Definition
Issues Surrounding the Management of Patients Who Present to the Emergency Department with Subtherapeutic Phenytoin Levels and a History of Seizures Edwin.
What is the Best Way to Provide a Phenytoin Load? Edwin Kuffner, MD Rocky Mountain Poison and Drug Center University of Colorado.
M ONITORING A DVERSE D RUG R EACTIONS (ADR S ) Dr. Dorothy Aywak 1.
Seizures: Nuts and Bolts National Pediatric Nighttime Curriculum Written by Anna Lin, MD Lucile Packard Children’s Hospital.
Epilepsy 2 Dr. Hawar A. Mykhan.
Neurological Emergencies Dr. Amal Alkhotani MBBCH, FRCPC, Epilepsy and EEG.
Seizures: Nuts and Bolts Nightfloat Curriculum Lucile Packard Children’s Hospital Residency Program.
Prepared by: Raed A. AL-Mohiza Directed by: Dr. Hesham Abo-Audah
Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.
Pharmacokinetics Questions
Clinical Policy: Critical Issues for the Evaluation and Management of Adult Patients Presenting With Seizures Andy Jagoda, MD, FACEP Professor of Emergency.
Status Epilepticus (SE): Rx Following Benzodiazepine Use Edward Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois.
Managing Seizure Patients in SE Following the Use of the Benzodiazepines.
First Line Therapy in Acute Seizure Management William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert Wood Johnson University Hospital.
Pediatric Prehospital Seizure Management: Evidence Based Guidelines and State of Care in CO Kathleen Adelgais, MD MPH Pediatric Emergency Medicine Children’s.
Andy S. Jagoda, MD 1 Seizure and Status Epilepticus Therapeutics: A 2005 Update.
Adult Seizure and SE Patient ED Care: Crossfire Edward P. Sloan, MD, MPH, FACEP 1.
Benzodiazepines What are the Best Non-IV Parenteral Options for a Seizing Patient? William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert.
Managing and Detecting Seizures in the ICU Special thanks to: Katherine Nickels, MD Assistant Professor of Neurology and Pediatrics Mayo Clinic.
P HARMACOTHERAPY IV S TATUS E PILEPTICUS Rowa’ Al Ramah 1.
ACEP Clinical Policy: ACEP Clinical Policy: Critical Issues for the Evaluation and Management of Adult Patients Presenting With Seizures William C. Dalsey,
Edward P. Sloan, MD, MPH, FACEP Putting it All Together with Seizure Clinical Policies: Making Good Clinical Decisions & Improving ED Seizure Patient Care.
Drug-Induced Seizures (in 15 minutes or Less) Robert S. Hoffman, MD Director, NYC Poison Center Associate Professor Emergency Medicine and Medicine NYU.
J. Stephen Huff, MD 1 What the ACEP Seizure Clinical Policy Doesn’t Tell Us about Adult Seizure and Status Epilepticus Patients… What the ACEP Seizure.
Edward P. Sloan, MD, MPH, FACEP Optimizing Seizure and SE Patient Management: Seizure Therapies Workshop and Clinical Policy Review.
How and Why Drugs Work Chapter 5
Jason Haag Intern Conference. Case 34 y.o. with h/o seizure disorder presents to ED with increased seizure frequency. He states he’s had 4 tonic-clonic.
Preparing & administering Infusions Mark Tomlin Consultant Pharmacist: Critical Care Southampton University Hospitals NHS Trust.
INTRAVENOUS INFUSION.
Background Collection of S & O Information Data: – CC, HPI, PMH, PSHx, Demographics – Medication history including compliance etc. – VS, ROS, Lab, other.
Management. Goals of emergency management for status epilepticus Ensure adequate brain oxygenation and cardiorespiratory function Terminate clinical and.
Managing Seizure Patients in SE Following the Use of the Benzodiazepines.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 3 Therapeutic Range.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 35 Intravenous Medications.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 13 Antiepileptic Drugs.
Status epilepticus the paeds emerg perspective Stephen C. Porter MD MPH MSc Division Chief, Pediatric Emergency Medicine The Hospital for Sick Children.
First Line Therapy in Acute Seizure Management: Focusing on the Pediatric Patient William C. Dalsey, MD, FACEP, MBA Department of Emergency Medicine Robert.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Calculation of Doses Prof. Dr. Henny Lucida, Apt.
Drug Dosages and Intravenous Calculations
Prof. Dr. Henny Lucida, Apt
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Clinical Pharmacokinetic Equations and Calculations
Danielle DelVillano, Pharm.D.
Types of Syringes Types of syringes are shown: A, 5-mL syringe. B, 3-mL syringe. C, Tuberculin syringe marked in 0.01 (hundredths) for doses less than.
ALLIE PUNKE PHARMCOKINETICS. PHENYTOIN THE BASICS What is the volume of distribution: Regular floor patient: L/kg Critically ill patient: 0.8.
STATUS EPILEPTICUS STATUS EPILEPTICUS Time for a New Guideline for Management Prof Ashraf Abdou NEUROPSYCHIATRY DEPARTMENT FACULTY OF MEDICINE ALEXANDRIA.
Anticonvulsants: Phenytoin
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Presentation On Routes of drug administration & it’s significance
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Introduction; Scope of Pharmacology Routes of Drug Administration
Anticonvulsants: Valproic acid
Calcium Chloride Christopher J. Fullagar, MD, EMT-P, FACEP
Clinical Pharmacokinetics
Status Epilepticus: Clinical Features, Pathophysiology, and Treatment
Pharmcokinetics Allie punke.
Chapter 35 Intravenous Medications
TCA Poisoning.
Fundamental Nursing Chapter 35 Intravenous Medications
 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Chapter 35: Intravenous Medications
Presentation transcript:

Issues Surrounding the Management of Patients Who Present to the ED with Subtherapeutic Phenytoin Levels and a History of Seizures J. Stephen Huff, MD Modified from material prepared by Edwin Kuffner, MD Rocky Mountain Poison and Drug Center University of Colorado

J. Stephen Huff, MD Key Clinical Questions What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED?

J. Stephen Huff, MD Case Presentation 35 year-old otherwise healthy male presents to the emergency department after having a seizure Past Medical History: seizures since childhood, last seizure 2 years ago Medications: ran out of phenytoin 2 weeks ago Physical Exam: normal vital signs, normal mental status and normal physical exam Serum phenytoin level: undetectable

What is the most effective phenytoin or fosphenytoin dosing strategy for preventing short term seizure recurrence in a patient with a pre-existing seizure disorder who presents to the emergency department within 24 hours of having had a seizure without status epilepticus and who is determined to have a “subtherapeutic” serum phenytoin level? J. Stephen Huff, MD

What Common Dosing Strategy Would you Use? A.Administer a loading dose of intravenous phenytoin and start/restart daily oral maintenance doses B.Administer a loading dose of intravenous fosphenytoin and start/restart daily oral maintenance doses C.Administer a loading dose of oral phenytoin and start/restart daily oral maintenance doses D.Start/restart daily oral maintenance doses without administering a loading dose

J. Stephen Huff, MD What is the Relationship Between a “Therapeutic” Serum Phenytoin Level and Seizure Prevention? Many patients remain seizure free at levels less than 10 mg/L and some patients require levels greater than 20 mg/L for seizure control. 1 At levels greater than 20 mg/L patients are more likely to have adverse events but many patients will experience adverse events at “therapeutic levels”. 2 1) Carter: Arch Neurol Psych 1958 and Leppick: Adv Neurol ) Ambrosetto: Epilepsia 1977 and Product information

Although achieving a “therapeutic” serum phenytoin level between mg/L may be a measure of pharmacokinetic efficacy a more relevant measure of clinical efficacy should be prevention of seizure recurrence with an acceptable adverse effects profile. J. Stephen Huff, MD

By What Route of Administration can a Serum Phenytoin Level > 10 mg/L be Achieved? A level > 10 mg/L can be achieved: Immediately following an intravenous loading dose 1 Within 3-10 hours in some cases and within 24 hours in most cases following an oral loading dose 2 Within 3-7 days following daily maintenance dosing without a loading dose 3 Within 1-2 hours in most cases and within 24 hours in almost all cases following an intramuscular loading dose 4 1) Carducci, Kugler, Leppick, Salem 2) Osborn, Rantakorn, Record, Wilder 3) Buchanan Gugler Svensmark 4) Boucher, Browne, Kugler, Uthman, Wilder

Regardless of the initial dosing strategy patients require daily maintenance doses to maintain the serum level > 10 mg/L. Less than 20% of adult patients taking 300 mg/day will achieve a serum level > 10 mg/L. 1 1) Buchanan, Gugler J. Stephen Huff, MD

Phenytoin Stabilizes membrane Na + channels Regulates Ca ++ channels Effective in generalized seizures and status Seizure termination in 40% to 80% of patients 18 mg/kg loading dose results in therapeutic (10  g/mL) levels up to 24 h

J. Stephen Huff, MD What Adverse Events are Associated with Oral, Intravenous and Intramuscular Dosing of Phenytoin and Fosphenytoin? Irrespective of dosing strategy ataxia, nystagmus and somnolence are common. Following intravenous dosing: Adverse local effects: phlebitis, purple glove syndrome, tissue necrosis 1 Adverse systemic effects: impaired myocardial contractility, dysrhythmias, hypotension, cardiac arrest 2 1) Comer, Marchetti, O’Brien, Kilarski 2) Earnst, Russell, York

J. Stephen Huff, MD Phenytoin Limitations Toxic diluents high pH solution Cardiac and soft tissue complications-“purple hand” Hypotension rate/infusion related often requires slowing Limitations

J. Stephen Huff, MD

Fosphenytoin: Phosphate-Ester Prodrug Water soluble prodrug Converted to phenytoin, the active anticonvulsant Complete conversion in vivo to phenytoin therapeutic free phenytoin levels within 2.7 minutes (IV) Rapid infusion rate, enhanced protein binding

J. Stephen Huff, MD Fosphenytoin Advantages No toxic diluents – pH 8.7 – compatible with IV fluids Less pain and fewer infusion – site complications Faster IV infusion rates – up to 150 PE/min – faster free phenytoin levels Advantages

J. Stephen Huff, MD IM Fosphenytoin Use Single site injections >20 cc possible Therapeutic levels achieved by 30 min No difference in pain placebo vs fosphenytoin single vs multiple site injection Only mild irritation noted, regardless of volume

J. Stephen Huff, MD Fosphenytoin Dosing: Phenytoin Equivalents Dosing is equivalent to phenytoin dosing Phenytoin solution is 50 mg/mL Fosphenytoin solution is 50 PE/mL 1 g fosphenytoin PEs = 1 g phenytoin Include PE and infusion rate in ordering fosphenytoin

Both local and systemic adverse effects are reported much less common with fosphenytoin than with intravenous phenytoin. 1 1) Boucher, Jameson, Henken J. Stephen Huff, MD

What are the Costs of Intravenous Phenytoin, Fosphenytoin and Oral Phenytoin? It costs approximately: $95.00 for 1000 mg of fosphenytoin $5.50 for 1000 mg of parenteral phenytoin $5.00 for 1000 mg of oral phenytoin

J. Stephen Huff, MD What is the Risk of Seizure Recurrence in a Discharged ED Patient? Data on the risk of seizure recurrence is commonly reported in years not days or weeks. It is difficult to compare studies because: The background incidence of short term seizure recurrence is unknown. Most studies included patients with many different etiologies for their seizures. 6-20% is a rough estimate Cranford, Huff, Leppick, Osborn

J. Stephen Huff, MD What the Literature Can Tell Us A serum phenytoin level > 10 mg/L can be achieved by all of the common contemporary dosing strategies and by intramuscular fosphenytoin administration. Fewer adverse effects are associated with administration of fosphenytoin than parenteral phenytoin preparations. Fosphenytoin remains considerably more expensive than parenteral phenytoin.

J. Stephen Huff, MD What the Literature Cannot Yet Tell Us Whether there is a difference in the short term rate of seizure recurrence between the different common dosing strategies

Emergency physicians who understand the pharmacokinetic, pharmacoeconomic and adverse event profiles of phenytoin and fosphenytoin as well as the limitations of the medical literature are best suited to help their patients make informed decisions regarding the different dosing strategies. J. Stephen Huff, MD

Practical Recommendations When I want to achieve a “therapeutic serum phenytoin level” prior to ED discharge, I* administer fosphenytoin or phenytoin IV Examples Prolonged seizure History of multiple seizures or status epilepticus Following emergency department discharge the patient is likely to be in an environment/situation where another seizure carries an increased risk of morbidity or mortality Medicolegal concerns

J. Stephen Huff, MD Practical Recommendations In order to minimize the adverse local and systemic effects associated with intravenous dosing, when available, administer fosphenytoin Examples Poor intravenous access or small intravenous catheters Agitated patients Suboptimal supervision during dosing Medicolegal concerns

J. Stephen Huff, MD Practical Recommendations In order to minimize the time a patient is in the emergency department, when cost is especially an important issue and when the indication for phenytoin therapy is questionable administer oral phenytoin Examples Emergency department resources are at a critical level Alcohol withdrawal patient whose seizures are likely partially due to alcohol withdrawal

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED? Key Learning Points

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? Variable between individuals…. Key Learning Points

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED? Key Learning Points

J. Stephen Huff, MD By what route of administration can a serum phenytoin level > 10 mg/L be achieved? Oral phenytoin loadinig, intravenous phenytoin or fosphenytoin administration, or IM phenytoin administration will all yield levels > over variable times Key Learning Points

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED? Key Learning Points

J. Stephen Huff, MD What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? All routes will have dizziness or nystagmus with high levels Too rapid intravenous administration of phenytoin or fosphenytoin may yield cardiac arrhythmias or hypotension, perhaps more with phenytoin Soft tissue necrosis may follow extravasation of phenytoin Key Learning Points

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED? Key Learning Points

J. Stephen Huff, MD What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? $95.00 for 1000 mg of fosphenytoin $5.50 for 1000 mg of parenteral phenytoin $5.00 for 1000 mg of oral phenytoin Key Learning Points

J. Stephen Huff, MD What is the relationship between a “therapeutic” serum phenytoin level and seizure prevention? By what route of administration can a serum phenytoin level > 10 mg/L be achieved? What adverse events are associated with oral, IV, and intramuscular dosing of phenytoin and fosphenytoin? What are the costs of intravenous phenytoin and fosphenytoin and oral phenytoin administration? What is the risk of seizure recurrence in a patient that is discharged from the ED? Key Learning Points

J. Stephen Huff, MD What is the risk of seizure recurrence in a patient that is discharged from the ED? UNKNOWN Key Learning Points

J. Stephen Huff, MD What Common Dosing Strategy Would you Use NOW? A.Administer a loading dose of intravenous phenytoin and start/restart daily oral maintenance doses B.Administer a loading dose of intravenous fosphenytoin and start/restart daily oral maintenance doses C.Administer loading dose of oral phenytoin and start/restart daily oral maintenance doses D.Start/restart daily oral maintenance doses without administering a loading dose